Elevated interleukin-32 expression in granulomatosis with polyangiitis

Rheumatology (United Kingdom)

Volumn 51, Issue 11, 2012, Pages 1979-1988

  Bae, Suyoung ^a   Kim, Yong Gil ^b   Choi, Jida ^a   Hong, Jaewoo ^a   Lee, Siyoung ^a   Kang, Taebong ^a   Jeon, Hyunjhung ^a   Hong, Kwangwon ^a   Kim, Eusom ^a   Kwak, Areum ^a   Lee, Chang Keun ^b   Yoo, Bin ^b   Park, Yong Beom ^c   Song, Eun Young ^d   Kim, Soohyun ^a  

^a Konkuk University   (South Korea)

^b Asan Medical Center   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

Cytokine; Granulomatosis with polyangiitis; IL 32; Inflammation; Neutrophil PR3

Indexed keywords

INTERLEUKIN 32; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOMATOSIS; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; NORTHERN BLOTTING; POLYANGIITIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT RESPONSE; VASCULITIS;

ADULT; AGED; BLOTTING, NORTHERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKINS; LEUKOCYTES; MALE; MIDDLE AGED; MYELOBLASTIN; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 84867836169     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes163     Document Type: Article

References (49)

1. Hong J, Bae S, Kang Y et al. Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFalpha and IL-1beta. Cytokine 2010; 49: 171-6.
2. Kim KH, Shim JH, Seo EH et al. Interleukin-32 monoclonal antibodies for immunohistochemistry, western blotting, and ELISA. J Immunol Methods 2008; 333: 38-50.
3. Li W, Liu Y, Mukhtar MM et al. Activation of interleukin-32 pro-inflammatory pathway in response to influenza a virus infection. PLoS One 2008; 3: e1985.
4. Li W, Yang F, Liu Y et al. Negative feedback regulation of IL-32 production by inos activation in response to dsRNA or influenza virus infection. Eur J Immunol 2009; 39: 1019-24.
5. Nishida A, Andoh A, Inatomi O, Fujiyama Y. Interleukin-32 expression in the pancreas. J Biol Chem 2009; 284: 17868-76.
6. Seo EH, Kang J, Kim KH et al. Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol 2008; 18: 1606-12.
7. Sorrentino C, Di Carlo E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 2009; 180: 769-79.
8. Jaekal J, Jhun H, Hong J et al. Cloning and characterization of bovine interleukin-32 beta isoform. Vet Immunol Immunopathol 2010; 137: 166-71.
9. Hasegawa H, Thomas HJ, Schooley K, Born TL. Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membraneassociated protein. Cytokine 2011; 53: 74-83.
10. Lee S, Kim S, Bae S et al. Interleukin-32 gamma specific monoclonal antibody and developing IL-32 specific ELISA. Hybridoma 2010; 29: 501-9.
11. Bai X, Kim SH, Azam T et al. IL-32 is a host protective cytokine against mycobacterium tuberculosis in differentiated THP-1 human macrophages. J Immunol 184: 3830-40.
12. Kundu M, Basu J. IL-32: an emerging player in the immune response network against tuberculosis? PLoS Med 2006; 3: e274.
13. Netea MG, Azam T, Lewis EC et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-gamma-dependent mechanism. PLoS Med 2006; 3: e277.
14. Alsaleh G, Sparsa L, Chatelus E et al. Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 2010; 12: R135.
15. Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y. Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 2008; 14: 5154-61.
16. Heinhuis B, Koenders MI, van de Loo FA et al. IL-32{gamma} and streptococcus pyogenes cell wall fragments synergise for IL-1-dependent destructive arthritis via upregulation of TLR-2 and NOD2. Ann Rheum Dis 2010; 69: 1866-72.
17. Joosten LA, Netea MG, Kim SH et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 2006; 103: 3298-303.
18. Kim YG, Lee CK, Oh JS, Kim SH, Kim KA, Yoo B. Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes. Arthritis Rheum 2010; 62: 515-23.
19. Netea MG, Lewis EC, Azam T et al. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci USA 2008; 105: 3515-20.
20. Shioya M, Nishida A, Yagi Y et al. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 2007; 149: 480-6.
21. Shoda H, Fujio K, Yamaguchi Y et al. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther 2006; 8: R166.
22. Bae S, Choi J, Hong J et al. Generation of anti-proteinase monoclonal antibodies and development of immunological methods to detect endogenous proteinase 3. Hybridoma 2010; 29: 17-26.
23. Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci USA 2006; 103: 3316-21.
24. Kim S, Lee S, Her E et al. Proteinase 3-processed form of the recombinant IL-32 separate domain. BMB Rep 2008; 41: 814-9.
25. Goldschmeding R, van der Schoot CE, ten Bokkel Huinink D et al. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 1989; 84: 1577-87.
26. Garwicz D, Lindmark A, Hellmark T, Gladh M, Jogi J, Gullberg U. Characterization of the processing and granular targeting of human proteinase 3 after transfection to the rat RBL or the murine 32D leukemic cell lines. J Leukoc Biol 1997; 61: 113-23.
27. Rao NV, Rao GV, Marshall BC, Hoidal JR. Biosynthesis and processing of proteinase 3 in U937 cells. Processing pathways are distinct from those of cathepsin G. J Biol Chem 1996; 271: 2972-8.
28. McGuire MJ, Lipsky PE, Thiele DL. Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I. J Biol Chem 1993; 268: 2458-67.
29. Lindmark A, Garwicz D, Rasmussen PB, Flodgaard H, Gullberg U. Characterization of the biosynthesis, processing, and sorting of human hbp/cap37/azurocidin. J Leukoc Biol 1999; 66: 634-43.
30. Lindmark A, Persson AM, Olsson I. Biosynthesis and processing of cathepsin g and neutrophil elastase in the leukemic myeloid cell line U-937. Blood 1990; 76: 2374-80.
31. Fujinaga M, Chernaia MM, Halenbeck R, Koths K, James MN. The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies. J Mol Biol 1996; 261: 267-78.
32. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev 2001; 1: 135-45.
33. Chuang TH, Ulevitch RJ. Cloning and characterization of a sub-family of human toll-like receptors: HTLR7, HTLR8 and HTLR9. Eur Cytokine Netw 2000; 11: 372-8.
34. Fukui R, Saitoh S, Matsumoto F et al. Unc93B1 biases toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J Exp Med 2009; 206: 1339-50.
35. Netea MG, Azam T, Ferwerda G et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 2005; 102: 16309-14.
36. Choi J, Bae S, Hong J et al. Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis. Proc Natl Acad Sci USA 2010; 107: 21082-6.
37. Nold MF, Nold-Petry CA, Pott GB et al. Endogenous IL-32 controls cytokine and hiv-1 production. J Immunol 2008; 181: 557-65.
38. Rasool ST, Tang H, Wu J et al. Increased level of IL-32 during human immunodeficiency virus infection suppresses HIV replication. Immunol Lett 2008; 117: 161-7.
39. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-7.
40. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
41. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994; 87: 671-8.
42. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Carruthers DM, Moots R. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol 1998; 37: 57-63.
43. Decker P. Nucleosome autoantibodies. Clin Chim Acta 2006; 366: 48-60.
44. Kasaian MT, Casali P. B-1 cellular origin and VH segment structure of IgG, IgA, and IgM anti-DNA autoantibodies in patients with systemic lupus erythematosus. Ann NY Acad Sci 1995; 764: 410-23.
45. Munoz LE, Gaipl US, Herrmann M. Predictive value of anti-dsDNA autoantibodies: importance of the assay. Autoimmun Rev 2008; 7: 594-7.
46. Pisetsky DS. Anti-DNA and autoantibodies. Curr Opin Rheumatol 2000; 12: 364-8.
47. Stollar BD. Antibodies to DNA. CRC Crit Rev Biochem 1986; 20: 1-36.
48. Stollar BD. Molecular analysis of anti-DNA antibodies. FASEB J 1994; 8: 337-42.
49. Swaak T, Smeenk R. Clinical significance of antibodies to double stranded DNA (dsDNA) for systemic lupus erythematosus (SLE). Clin Rheumatol 1987; 6(Suppl 1): 56-73.